Investors who take an interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) should definitely note that the CEO, President & Director, Alexander Sapir, recently paid US$11.35 per share to buy US$492k ...
Source LinkInvestors who take an interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) should definitely note that the CEO, President & Director, Alexander Sapir, recently paid US$11.35 per share to buy US$492k ...
Source Link
Comments